Chrysalin Phase III Data Fails To Crystallize Future Of Synthetic Peptide
This article was originally published in The Pink Sheet Daily
OrthoLogic’s Chrysalin fails to meet its Phase III trial primary endpoint; a Phase IIb dose ranging study will determine the drug’s fate.
You may also be interested in...
Two of the leading medical journals are offering opposing viewpoints on mandatory human papilloma virus vaccination, with experts contributing perspective pieces that directly reflect the larger political and social division over the issue
FDA's "not approvable" action on Merck's Vioxx follow-on Arcoxia for the treatment of symptoms of osteoarthritis could be indicative of a conservative regulatory climate at the agency
A bill introduced by Rep. Bobby Rush, D-Ill., banning "reverse" settlements between brand and generic companies would give the Federal Trade Commission the power to allow any such agreement it deems furthers market competition